Related Experiment Video

Updated: Aug 19, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression

Eliana Perissinotto1, Giuliana Cavalloni, Francesco Leone

  • 1Department of Oncological Sciences and Laboratories of Clinical Oncology, University of Turin Medical School, IRCC Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo, Turin, Italy.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 11, 2005
PubMed

Insights

Osteosarcoma metastasis to the lungs is driven by the CXCR4/SDF-1 pathway. Inhibiting this pathway with drugs can prevent cancer spread, offering new treatment strategies for osteosarcoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Osteosarcoma frequently metastasizes to the lungs and bone despite aggressive treatments.
  • The underlying mechanisms driving this preferential metastatic spread remain largely elusive.
  • The chemokine receptor 4 (CXCR4)/stromal cell-derived factor 1 (SDF-1) system is implicated in cancer cell homing.

Purpose of the Study:

  • To investigate the role of the CXCR4/SDF-1 axis in osteosarcoma cell metastasis.
  • To analyze the expression and function of CXCR4 and SDF-1 in osteosarcoma cells.
  • To evaluate the potential of targeting the CXCR4/SDF-1 pathway for therapeutic intervention.

Main Methods:

  • Analysis of CXCR4 and SDF-1 protein expression in osteosarcoma cell lines.
  • In vitro assays to assess SDF-1's effects on cell migration, adhesion, and proliferation.
  • In vivo mouse model to evaluate the efficacy of a CXCR4 inhibitor (T134 peptide) in preventing lung metastasis.

Main Results:

  • Osteosarcoma cells expressing CXCR4 exhibited SDF-1-guided migration and enhanced adhesion to endothelial and bone marrow stromal cells.
  • SDF-1 treatment increased the production of matrix metalloproteinase-9 (MMP-9) in osteosarcoma cells.
  • Administration of a CXCR4 inhibitor (T134 peptide) successfully prevented lung metastasis in a mouse model.

Conclusions:

  • The CXCR4/SDF-1 axis plays a critical role in the homing and metastasis of osteosarcoma cells, particularly to the lungs.
  • High SDF-1 concentration in the lungs may explain the preferential metastatic site.
  • Targeting the CXCR4/SDF-1 pathway with inhibitors (e.g., small molecules, antibodies) represents a promising strategy to prevent osteosarcoma dissemination.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...